CANDEL THERAPEUTICS

Candel Therapeutics Announces Data from Phase 1 Trial of CAN-3110 in Recurrent High-Grade Glioma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Friday, June 4, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Nestin, Proteins, American Society of Clinical Oncology, Branches of biology, Medicine, Cancer, CAN-3110, Candel Therapeutics, CAN-3110, CANDEL THERAPEUTICS

The data are presented today in an Oral Abstract Session of the Clinical Science Symposium at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • The data are presented today in an Oral Abstract Session of the Clinical Science Symposium at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • As of the data cutoff date of April 21, 2021:
    30 patients were evaluable for safety.
  • Based on these data, we are excited to advance this innovative agent into further clinical trials."
  • Nestin is highly expressed in glioma cells and other tumor tissue but is absent in the healthy adult brain.

Candel Therapeutics’ CAN-3110 Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Thursday, April 29, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Virotherapy, Oncolytic virus, Immunotherapy, Experimental cancer treatments, Biotechnology, CAN-3110, Candel Therapeutics, CAN-3110, CANDEL THERAPEUTICS

b'Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that an abstract has been accepted for oral presentation at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held virtually from June 4-8, 2021.

Key Points: 
  • b'Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that an abstract has been accepted for oral presentation at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held virtually from June 4-8, 2021.
  • For more information on this clinical study, please visit https://www.clinicaltrials.gov/ct2/show/NCT03152318?term=candel&draw=3\nCandel is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies.
  • Our approach combines an in-depth knowledge of viral immunotherapy with extensive clinical experience across a wide range of indications.
  • To learn more, visit www.candeltx.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210429005404/en/\n'